OrthogenRx Announces Response in The Journal of Bone and Joint Surgery

The recently published response counters this position and addresses some recently reported economic and medical benefits not acknowledged within the AAOS CPGs.

OrthogenRx Launches TriVisc® (sodium hyaluronate) in the US

1/23/19: TriVisc is the first medical device in over 20 years to demonstrate clinical effectiveness & secure FDA approval under Section 216 of the FDA Modernization Act (1997).